Emerging pharmacology of nerve growth factor

Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(6):851-60. doi: 10.1016/0278-5846(91)90013-q.

Abstract

1. Partial transection of the septo-hippocampal pathway decreased measures of presynaptic cholinergic function in the rat hippocampal formation. 2. Chronic intraventricular treatment with recombinant human nerve growth factor attenuated lesioned-induced deficits in cholinergic function. Following nerve growth factor treatment measures of choline acetyltransferase activity, acetylcholine synthesis and release were significantly increased compared to cytochrome c-treated lesioned animals. 3. Single injections of nerve growth factor were ineffective in altering lesioned-induced deficits in cholinergic function. 4. Chronic nerve growth factor treatment was ineffective in increasing presynaptic cholinergic function if administered 3 or more weeks following fimbrial transections. 5. The nerve growth factor-induced increases of presynaptic cholinergic function persisted for 3 weeks following the cessation of chronic 3 week nerve growth factor treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetylcholine / biosynthesis
  • Animals
  • Choline / metabolism
  • Choline O-Acetyltransferase / metabolism
  • Female
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / physiology
  • In Vitro Techniques
  • Injections, Intraventricular
  • Nerve Growth Factors / administration & dosage
  • Nerve Growth Factors / pharmacology*
  • Nerve Tissue Proteins / biosynthesis
  • Neural Pathways / physiology
  • Parasympathetic Nervous System / drug effects
  • Rats
  • Rats, Inbred Strains
  • Recombinant Proteins / pharmacology
  • Synapses / drug effects

Substances

  • Nerve Growth Factors
  • Nerve Tissue Proteins
  • Recombinant Proteins
  • Choline O-Acetyltransferase
  • Choline
  • Acetylcholine